Table 1.
Characteristics of patients with exocrine pancreatic cancer in Korea from 2006 to 2017
| Variable | Total (2006–2017) (n=62,209) | Period I (2006–2011) (n=26,212) | Period II (2012–2017) (n=35,997) |
|---|---|---|---|
| Age at diagnosis (yr) | |||
| 0–39 | 859 (1.4) | 381 (1.5) | 478 (1.3) |
| 40–49 | 3,396 (5.5) | 1,631 (6.2) | 1,765 (4.9) |
| 50–59 | 10,159 (16.3) | 4,351 (16.6) | 5,808 (16.1) |
| 60–69 | 16,654 (26.8) | 7,523 (28.7) | 9,131 (25.4) |
| 70–79 | 20,485 (32.9) | 8,436 (32.2) | 12,049 (33.5) |
| ≥ 80 | 10,656 (17.1) | 3,890 (14.8) | 6,766 (18.8) |
| Sex | |||
| Male | 33,554 (53.9) | 14,442 (55.1) | 19,112 (53.1) |
| Female | 28,655 (46.1) | 11,770 (44.9) | 16,885 (46.9) |
| Location | |||
| Head of pancreas (C25.0) | 24,773 (39.8) | 10,358 (39.5) | 14,415 (40.1) |
| Body and tail of pancreas (C25.1-2) | 20,225 (32.5) | 7,510 (28.7) | 12,715 (35.3) |
| Others (C25.3-8) | 4,339 (7.0) | 1,808 (6.9) | 2,531 (7.0) |
| Pancreas, NOS (C25.9) | 12,872 (20.7) | 6,536 (24.9) | 6,336 (17.6) |
| SEER stage | |||
| Localized | 6,120 (9.8) | 2,657 (10.1) | 3,463 (9.6) |
| Regional | 19,108 (30.7) | 7,635 (29.1) | 11,473 (31.9) |
| Distant | 26,977 (43.4) | 10,963 (41.8) | 16,014 (44.5) |
| Unknown | 10,004 (16.1) | 4,957 (18.9) | 5,047 (14.0) |
| First course of treatment (FT) | |||
| Surgical FT | 13,694 (22.0) | 5,388 (20.6) | 8,306 (23.1) |
| Non-surgical FT | 17,861 (28.7) | 6,801 (25.9) | 11,060 (30.7) |
| No active treatment | 28,912 (46.5) | 13,098 (50.0) | 15,814 (43.9) |
| Unknown | 1,742 (2.8) | 925 (3.5) | 817 (2.3) |
| Histology | |||
| Ductal adenocarcinoma excluding cystic or mucinous (DAC) | 59,685 (95.9) | 25,244 (96.3) | 34,441 (95.7) |
| Ductal specified as mucinous or cystic adenocarcinoma (ADCm&c) | 2,338 (3.8) | 878 (3.4) | 1,460 (4.1) |
| Acinar cell carcinoma (ACC) | 186 (0.3) | 90 (0.3) | 96 (0.3) |
Values are presented as number (%). Non-surgical FT, chemotherapy with/without/or radiation therapy; NOS, not otherwise specified; SEER, Surveillance, Epidemiology, and End Results.